Journal of Clinical Oncology, Vol 16, 3398-3405, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

NA Dawson
Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA. nancy_a.dawson@wramaa.chcs.amedd.army.mil

PURPOSE: To survey eligibility and response criteria for clinical trials in hormone-refractory prostate cancer (HRPC). METHODS: Thirty- five established investigators of HRPC completed a 125-question survey. RESULTS: There was a general consensus that criteria for clinical trial entry would include progression based on an increasing prostate- specific antigen (PSA) level (94% of investigators), an increase in measurable disease (91%), and/or appearance of new bone lesions on bone scan (83%). Most believed that castrate levels of testosterone (77%) and progression after antiandrogen withdrawal (97%) should be documented before study enrollment. Continuation of testicular androgen suppression would be required by 82%. Seventy-seven percent favored separate reports on response rates in bone, measurable disease, symptoms, and biochemical markers (primarily PSA levels), rather than a composite response. Ninety-four percent of the investigators accepted changes in PSA level as a surrogate end point of response. However, interpretation by these investigators of a PSA data set similar to what might be observed in a clinical trial showed marked discordance. Survival is the end point of most importance to 94% of these investigators. Response based on changes in measurable disease, time to progression, response duration, PSA level decrease, or quality-of-life improvement were of similar weighted value as a clinical trial end point and were rated as less important to these investigators than survival (P < 10(-8)). CONCLUSION: This survey indicates some consensus on eligibility and concomitant treatments for clinical studies in HRPC. The use of multiparameter assessment of response and PSA level as a surrogate end point have been widely adopted.

This article has been cited by other articles:

				E. J. Small, A. McMillan, M. Meyer, L. Chen, W. J. Slichenmyer, P. F. Lenehan, and M. Eisenberger Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival J. Clin. Oncol., March 1, 2001; 19(5): 1304 - 1311. [Abstract] [Full Text] [PDF]

				E. J. Small, P. Fratesi, D. M. Reese, G. Strang, R. Laus, M. V. Peshwa, and F. H. Valone Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells J. Clin. Oncol., December 1, 2000; 18(23): 3894 - 3903. [Abstract] [Full Text] [PDF]

				G. J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger, W. D. Figg, B. Freidlin, S. Halabi, G. Hudes, et al. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., November 1, 1999; 17(11): 3461 - 3467. [Abstract] [Full Text] [PDF]

				D. Osoba, I. F. Tannock, D. S. Ernst, and A. J. Neville Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone J. Clin. Oncol., June 1, 1999; 17(6): 1654 - 1654. [Abstract] [Full Text] [PDF]

				H.-P. Schmid, A. Semjonow, R. Maibach, and N. A. Dawson Prostate-Specific Antigen Doubling Time: A Potential Surrogate End Point in Hormone-Refractory Prostate Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1644 - 1644. [Full Text] [PDF]